A Phase 3 interventional study of Xenon and Oxygen 30 % in Ischemic Stroke, sponsored by Negovsky Reanimatology Research Institute. Completed at 1 site in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-03.
Sponsored by Negovsky Reanimatology Research Institute · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Ischemic Stroke with a site in Russian Federation — 4 open to participants now, 4 under way, none of them phase 3. Ischemic Stroke · Russian Federation.
Among the 26 studies in Ischemic Stroke with a site in Russian Federation, this one is the 14th largest by enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2022, is one of 8 in phase 3, and was the 19th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →4 of the 26 studies in Ischemic Stroke with a site in Russian Federation are open now. Recruiting first, the newest first:
Neurotechnika · Sites in Russian Federation
Ages 18–80
Skolkovo Institute of Science and Technology · Sites in Russian Federation
Ages 35–70 · Healthy volunteers
Mikhail Zykov · Sites in Russian Federation
Ages 18+
Siberian Scientific Research and Test Center for Biomedical Engineering · Sites in Russian Federation
Ages 35–65 · Healthy volunteers
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 120 across the 19 interventional studies, 500 across the 7 observational. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 26 have an industry lead sponsor. The 10 most frequent:
Negovsky Reanimatology Research Institute is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Negovsky Reanimatology Research Institute has 1 study filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Ischemic Stroke with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In the Russian Federation, ischemic cerebral infarction is recorded annually in more than 450,000 people. It is the second most common cause of death after coronary heart disease.
The 30-day mortality rate after an ischemic cerebral infarction is more than 25%, and during the following year about half of the patients die. To date, all candidate neuroprotective drugs tested in various clinical trials have demonstrated insufficient efficacy . Therefore, the development of new approaches to the treatment of severe brain injuries of various etiologies is one of the most important tasks of critical condition medicine.
Brain damage due to stroke triggers a number of pathophysiological reactions, which are based on the accumulation of glutamate with the development of excitotoxicity. The effect of glutamate on NMDA receptors is one of the main factors of neurodegenerative disorders.
Xenon is an anesthetic whose neuroprotective properties have been shown in many experimental studies. Хenon inhalation after ischemia and reperfusion suppresses ischemic brain damage and tPA-induced cerebral hemorrhages, and damage to the blood-brain barrier.
The most interesting is a randomized controlled trial performed by R. Laitio et al. (2016), in which the use of xenon in combination with hypothermia in clinical practice was studied for the first time. In patients who have undergone community-acquired cardiac arrest, xenon inhalation at a concentration of 40 vol.% within 24 hours in combination with hypothermia, led to less damage to the white matter of the brain than with patients using hypothermia alone. The 6-month mortality rate was 27% in the xenon and hypothermia group and 35% in the hypothermia group.
It is important to note that today, despite a large pool of convincing preclinical studies proving the neuroprotective properties of xenon, there is not a single clinical study of its use in ischemic stroke.
Therefore, the research objectives is to determine whether the strategy of using xenon-oxygen mixture inhalation is better than oxygen-air mixture inhalation with respect to the change in scores on the NIHSS, Rankin and Glasgow coma scales on day 7, the duration of stay in the ICU and the frequency of nosocomial pneumonia.
In the Russian Federation, ischemic cerebral infarction is recorded annually in more than 450,000 people. It is the second most common cause of death after coronary heart disease.
The 30-day mortality rate after an ischemic cerebral infarction is more than 25%, and during the following year about half of the patients die, which is more than 200,000 people. The consequences of stroke belong to the first place among the causes of primary disability. No more than 15% of those who have suffered a stroke return to work or fully perform their previous household duties, and the rest, due to disability, need lifelong medical and social rehabilitation. To date, all candidate neuroprotective drugs tested in various clinical trials have demonstrated insufficient efficacy . Therefore, the development of new approaches to the treatment of severe brain injuries of various etiologies is one of the most important tasks of critical condition medicine.
Brain damage due to stroke triggers a number of pathophysiological reactions, which are based on the accumulation of glutamate with the development of excitotoxicity. The effect of glutamate on NMDA receptors is one of the main factors of neurodegenerative disorders.
Xenon is an anesthetic whose neuroprotective properties have been shown in many experimental studies. However, the clinical part is still presented rather modestly. After it was discovered that xenon is an inhibitor of NMDA receptors, it was shown that xenon can protect neuronal cell cultures from damage caused by NMDA, glutamate, or oxygen-glucose deprivation. It has been experimentally established that xenon is an inhibitor of tissue plasminogen activator (tPA) and dose-dependent inhibits tPA-induced thrombolysis; xenon inhalation after ischemia and reperfusion suppresses ischemic brain damage and tPA-induced cerebral hemorrhages, and damage to the blood-brain barrier.
Exposure to xenon after transient ischemia in rats leads to a decrease in the volume of infarction, depending on the concentration, exposure time and improvement of neurological function 7 days after ischemia. To date, a role has been discovered in the implementation of molecular mechanisms of xenon neuroprotection of double-pore potassium channels (TREK-1), which provide a basic ion current that weakens neuronal excitability, thereby protecting neurons from damage. The role of adenosine triphosphate (ATP)-sensitive potassium channels of the plasmalemma in the realization of the protective properties of xenon is also discussed in the scientific literature. It was shown that under in vitro conditions in the culture of neurons, xenon protected them from damage caused by glucose and oxygen deprivation by activating ATP-sensitive potassium channels in the plasmalemma. There is evidence of the effect of xenon inhalation on the phosphorylation of glycogen synthase-3ß, a key enzyme of the anti-apoptotic neuronal cascade, and an increase in the pool of enzymes involved in the antioxidant protection of the brain. An experimental study showed a distinct anti-inflammatory effect of this anesthetic, which consisted in an increase in the ability of neutrophils to spontaneous apoptosis and a decrease in the expression of adhesion molecules CD11b and CD66b on their surface after modeling an inflammatory reaction. Also, the anti-inflammatory properties of xenon were shown when modeling traumatic brain injury in vivo, when its exposure for 60 minutes caused a significant decrease in the expression of pro-inflammatory genes NF-kB1 and NF-kB2, responsible for the synthesis of cytokines and other molecules involved in inflammation. Considering that the inflammatory reaction that forms in the first hours of ischemic brain damage largely determines the severity of its further course, such an effect on neutrophils can reduce the severity of damage to nervous tissue.
The most interesting is a randomized controlled trial performed by R. Laitio et al. (2016), in which the use of xenon in combination with hypothermia in clinical practice was studied for the first time. In patients who have undergone community-acquired cardiac arrest, xenon inhalation at a concentration of 40 vol.% within 24 hours in combination with hypothermia, led to less damage to the white matter of the brain than with patients using hypothermia alone. The 6-month mortality rate was 27% in the xenon and hypothermia group and 35% in the hypothermia group. However, the study was not powerful enough.
It is important to note that today, despite a large pool of convincing preclinical studies proving the neuroprotective properties of xenon, there is not a single clinical study of its use in ischemic stroke.
Therefore, the research objectives is to determine whether the strategy of using xenon-oxygen mixture inhalation is better than oxygen-air mixture inhalation with respect to the change in scores on the NIHSS, Rankin and Glasgow coma scales on day 7, the duration of stay in the ICU and the frequency of nosocomial pneumonia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Xenon
Drug: Oxygen 30 %
Xenon is injected into the body by inhalation in the form of xenon-oxygen mixtures, in which the concentration of xenon is 30%, and oxygen is 30%. Xenon inhalation is carried out for 30 min daily for 3 days.
Oxygen-air mixture is injected into the body by inhalation. The oxygen concentration is 30%. Inhalation of oxygen-air mixture is carried out for 30 min daily for 3 days
National Institutes of Health Stroke Scale
Change of scores on the National Institutes of Health Stroke Scale. Minimal score equal 0. Maximal score equal 42. Less score means better outcome.
Time frame: 7 day
Rankin scale
Change in Rankin scale scores Minimal score equal 0. Maximal score equal 5. Less score means better outcome.
Time frame: day 7
Glasgow coma scale
Change of points on the Glasgow coma scale Minimal score equal 0. Maximal score equal 15. Less score means worse outcome.
Time frame: day 7
Duration of stay in the intensive care unit
day of the intensive care unit discharge - day of the randomization
Time frame: 28 days
Nosocomial pneumonia
The incidence of nosocomial pneumonia
Time frame: 28 days
Mortality
All cause mortality
Time frame: 28 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2022 to primary completion in Jan 2024, 24 months.
Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 24 months is below that.
Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Xenon
Negovsky Reanimatology Research Institute